Antiretroviral therapy for HIV prevention consultation
AGENDA: Day 1
OPENING SESSION
09:00
Welcome and opening remarks
Hiroki Nakatani
09:15
Background
[pdf 810kb]
Teguest Guerma
Meeting objectives, expected outcomes and working methods
[pdf 176kb]
Siobhan Crowley
09:30
Universal voluntary HIV testing and counselling and immediate ART: results of a modelling exercise
[pdf 1.26Mb] Brian Williams |
[pdf 2.09Mb] Reuben Granich
SCIENTIFIC AND TECHNICAL CONSIDERATIONS
Chair: Kevin M. De Cock
11:00
Universal voluntary testing and treatment: when to start and other research issues
[pdf 3.81Mb]
Carl Dieffenbach
Scientific evidence for the use of ART for HIV prevention
[pdf 979kb]
Julio Montaner
Commentary
[pdf 282kb]
Myron Cohen
12:00
Scientific evidence on HIV testing and counselling to prevent HIV transmission and increase access to prevention, treatment and care
[pdf 2.13Mb] Michael Sweat |
[pdf 2.48Mb] Susan Allen
ETHICAL, HUMAN RIGHTS AND COMMUNITY CONSIDERATIONS
Chair: Beri Hull
14:00
Community engagement and acceptance of ART for HIV prevention
Nonkosi Khumalo
People living with HIV perspectives on ART for HIV prevention
[pdf 166kb]
Kevin Moody
Human rights and ART for prevention
Lucy Cheshire
Gender perspectives on ART for HIV prevention
Mariangela Simao
Ethics of ART for HIV prevention as a public health intervention
[pdf 120kb]
Khoudia Sow
OPERATIONAL CONSIDERATIONS - ECONOMIC AND HEALTH SYSTEMS ISSUES
Chair: Wafaa El-Sadr
16:30
UNAIDS/WHO assumptions, methods and estimation of resource needs to achieve universal access [pdf 687kb]
Carlos Avila
Costs of scaling up and the current financial landscape
[pdf 491kb]
Tessa Edejer
Detailed programme costing of seek and immediately treat approaches in a hyperendemic setting
[pdf 352kb]
Jim Kahn
Commentary: The Global Fund perspective
Rifat Atun
Commentary: The PEPFAR perspective
Eric Goosby